Gustave Roussy and IntegraGen announced the achievement of one thousand genomic analyses utilizing their combined sequencing platform. The molecular profiles of cancer patients were analyzed as part of personalized medicine clinical trials being conducted at Gustave Roussy. The ability to deliver these results in less than three weeks demonstrates the capability of these teams to routinely sequence DNA (exome) and RNA (transcriptome) from tumors for clinical research purposes.

Link to press release